Aurobindo Pharma's Unit-III Gets FDA OAI After 11 Inspection Observations

The US FDA classified Aurobindo Pharma’s subsidiary (Eugia Unit-III) as 'Official Action Indicated' (OAI) following an inspection with 11 observations. This regulatory status signifies serious compliance issues, likely halting new product approvals from the facility and introducing significant operational risk.